ZA984077B - Peptide parathyroid hormone analogs - Google Patents
Peptide parathyroid hormone analogsInfo
- Publication number
- ZA984077B ZA984077B ZA984077A ZA984077A ZA984077B ZA 984077 B ZA984077 B ZA 984077B ZA 984077 A ZA984077 A ZA 984077A ZA 984077 A ZA984077 A ZA 984077A ZA 984077 B ZA984077 B ZA 984077B
- Authority
- ZA
- South Africa
- Prior art keywords
- parathyroid hormone
- hormone analogs
- peptide parathyroid
- peptide
- analogs
- Prior art date
Links
- 108090000445 Parathyroid hormone Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/635—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Endocrinology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physical Education & Sports Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biophysics (AREA)
- Diabetes (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US4647297P | 1997-05-14 | 1997-05-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA984077B true ZA984077B (en) | 1998-11-24 |
Family
ID=21943653
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA984077A ZA984077B (en) | 1997-05-14 | 1998-05-14 | Peptide parathyroid hormone analogs |
Country Status (20)
Country | Link |
---|---|
US (2) | US6472505B1 (hu) |
EP (1) | EP0986395A4 (hu) |
JP (1) | JP2001517957A (hu) |
KR (1) | KR100351213B1 (hu) |
CN (1) | CN1261281A (hu) |
AP (1) | AP9901686A0 (hu) |
AU (1) | AU746461B2 (hu) |
BG (1) | BG103957A (hu) |
BR (1) | BR9808786A (hu) |
CA (1) | CA2290443A1 (hu) |
EA (1) | EA002819B1 (hu) |
HU (1) | HUP0003349A3 (hu) |
IL (1) | IL132901A0 (hu) |
NO (1) | NO995568L (hu) |
OA (1) | OA11216A (hu) |
PL (1) | PL336803A1 (hu) |
SK (1) | SK151599A3 (hu) |
UA (1) | UA62967C2 (hu) |
WO (1) | WO1998051324A1 (hu) |
ZA (1) | ZA984077B (hu) |
Families Citing this family (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL138338A0 (en) | 1998-04-15 | 2001-10-31 | Aventis Pharm Prod Inc | Process for the preparation of resin-bound cyclic peptides |
US6316410B1 (en) * | 1999-09-22 | 2001-11-13 | National Research Council Of Canada | Parathyroid hormone analogues for the treatment of osteoporosis |
WO2003097690A2 (en) * | 2002-05-16 | 2003-11-27 | Theratechnologies Inc. | Pth derivatives resistant to skin proteases |
WO2004073587A2 (en) * | 2003-02-19 | 2004-09-02 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with parathyroid hormone receptor 1 (pthr1) |
CN1822853A (zh) * | 2003-07-15 | 2006-08-23 | 加拿大国家研究委员会 | 用于治疗特征在于过度增殖皮肤细胞的疾病的人类甲状旁腺激素环状类似物 |
US7439226B2 (en) * | 2003-09-30 | 2008-10-21 | The United States Of America As Represented By The Department Of Health And Human Services | Serine protease inhibitors |
US20060052306A1 (en) * | 2004-05-10 | 2006-03-09 | Nastech Pharmaceutical Company Inc. | GRAS composition for enhanced mucosal delivery of parathyroid hormone |
CN101151048A (zh) * | 2004-05-10 | 2008-03-26 | 纳斯泰克制药公司 | 增强甲状旁腺激素粘膜递送的组合物和方法 |
US20060052305A1 (en) * | 2004-05-10 | 2006-03-09 | Nastech Pharmaceutical Company Inc. | Method of treating osteoporosis using intranasal parathyroid hormone |
US20060127320A1 (en) * | 2004-05-10 | 2006-06-15 | Nastech Pharmaceutical Company Inc. | Method of delivering parathyroid hormone to a human |
JP5086254B2 (ja) | 2005-07-07 | 2012-11-28 | フルクルム エスピー リミテッド | Sp1ポリペプチド、変性sp1ポリペプチドおよびそれらの使用 |
US20070173447A1 (en) * | 2005-10-25 | 2007-07-26 | Nastech Pharmaceutical Company Inc. | Method for treating osteoporosis by intranasal delivery of teriparatide with an anti-resorptive agent |
CA2628945A1 (en) * | 2005-11-10 | 2007-05-24 | Board Of Control Of Michigan Technological University | Black bear parathyroid hormone and methods of using black bear parathyroid hormone |
US20080051332A1 (en) * | 2005-11-18 | 2008-02-28 | Nastech Pharmaceutical Company Inc. | Method of modulating hematopoietic stem cells and treating hematologic diseases using intranasal parathyroid hormone |
PL2084183T3 (pl) * | 2006-10-13 | 2010-10-29 | Lilly Co Eli | Pegylowane pth jako modulatory receptora pth i ich zastosowania |
WO2010086867A2 (en) | 2009-02-02 | 2010-08-05 | Ramot At Tel Aviv University Ltd. | Peptides, pharmaceutical compositions comprising same and uses thereof |
EP2344179A1 (en) | 2009-04-01 | 2011-07-20 | The Medical Research, Infrastructure, And Health Services Fund Of The Tel Aviv Medical Center | A method of regulating proliferation and differentiation of keratinocyes |
WO2010116375A1 (en) | 2009-04-08 | 2010-10-14 | Yeda Research And Development Co. Ltd. | Isolated peptides for regulating apoptosis |
US20120070449A1 (en) | 2009-05-28 | 2012-03-22 | Yeda Research And Development Co. Ltd. | Methods of treating inflammation |
SG10201406921SA (en) * | 2009-07-29 | 2014-11-27 | Kai Pharmaceuticals Inc | Therapeutic agents for reducing parathyroid hormone levels |
CA2782640A1 (en) | 2009-12-07 | 2011-06-16 | Michigan Technological University | Black bear parathyroid hormone and methods of using black bear parathyroid hormone |
WO2011138785A2 (en) | 2010-05-05 | 2011-11-10 | Rappaport Family Institute For Research In The Medical Sciences | Use of ccl1 in therapy |
CN103002906B (zh) * | 2010-05-13 | 2017-12-29 | 总医院有限公司 | 甲状旁腺激素类似物及其应用 |
US8901074B2 (en) | 2010-08-04 | 2014-12-02 | Ramot At Tel-Aviv University | Methods of treating autoimmune diseases of the central nervous system (CNS) and neurodegenerative diseases |
WO2012131680A2 (en) | 2011-03-28 | 2012-10-04 | Yeda Research And Development Co. Ltd. | Compositions and methods for treating inflammation |
EP2721686B1 (en) * | 2011-06-17 | 2018-11-28 | NantEnergy, Inc. | Ionic liquid containing sulfonate ions |
DK2823040T3 (en) | 2012-03-06 | 2018-11-19 | Cellect Biotherapeutics Ltd | DEVICES AND METHODS FOR SELECTING APOPTOSE SIGNALING RESISTANT CELLS AND APPLICATIONS THEREOF |
WO2015040609A1 (en) | 2013-09-17 | 2015-03-26 | Yeda Research And Development Co. Ltd. | Erk-derived peptides and uses thereof |
WO2015114633A1 (en) | 2014-01-30 | 2015-08-06 | Yissum Research And Development Company Of The Hebrew University Of Jerusalem Ltd. | Actin binding peptides and compositions comprising same for inhibiting angiogenes is and treating medical conditions associated with same |
WO2015145449A2 (en) | 2014-03-27 | 2015-10-01 | Yeda Research And Development Co. Ltd. | T-cell receptor cdr3 peptides and antibodies |
WO2016135716A1 (en) | 2015-02-26 | 2016-09-01 | Jacob Schneiderman | Methods and compositions relating to leptin antagonists |
AU2016291817A1 (en) | 2015-07-16 | 2018-02-22 | Biolinerx Ltd. | Compositions and methods for treating cancer |
WO2017122209A2 (en) | 2016-01-12 | 2017-07-20 | Yeda Research And Development Co. Ltd. | NF-kappaB INHIBITORS |
IL243838A (en) | 2016-01-28 | 2017-07-31 | Sp Nano Ltd | The composition containing sp1 protein and carbon nanoparticles and its uses |
IL243839B (en) | 2016-01-28 | 2018-01-31 | Sp Nano Ltd | Conductive wires |
EP3464322B1 (en) | 2016-06-05 | 2023-04-05 | Tel HaShomer Medical Research Infrastructure and Services Ltd. | Novel molecules for the treatment of inflammation |
WO2018037416A1 (en) | 2016-08-25 | 2018-03-01 | Yeda Research And Development Co. Ltd. | Methods and compositions for treating autoimmune diseases |
EP3548106B1 (en) | 2016-12-01 | 2023-01-04 | Ramot at Tel-Aviv University Ltd. | Combined treatment for nerve injuries |
EP3606615A1 (en) | 2017-04-07 | 2020-02-12 | Yissum Research and Development Company of the Hebrew University of Jerusalem Ltd. | Hair care compositions |
WO2018216011A1 (en) | 2017-05-23 | 2018-11-29 | Technion Research & Development Foundation Limited | Agents which inhibit gads dimerization and methods of use thereof |
WO2019016819A1 (en) | 2017-07-20 | 2019-01-24 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | NANOPARTICLE COMPOSITIONS |
IL253642A0 (en) | 2017-07-24 | 2017-09-28 | Seger Rony | Combined treatment for cancer |
IL253984A0 (en) | 2017-08-14 | 2017-09-28 | Yeda Res & Dev | Immunotherapy against aranviruses that bind through transferrin receptor 1 (tfr1 |
EP3717032B1 (en) | 2017-11-29 | 2023-02-15 | Ramot at Tel-Aviv University Ltd. | Methods of preventing or treating neurogenic shock |
EP3814385A4 (en) | 2018-07-11 | 2022-04-06 | KAHR Medical Ltd. | SIRPALPHA-4-1BBL VARIANT FUSION PROTEIN AND METHODS OF USE THEREOF |
IL265486A (en) | 2019-03-19 | 2020-09-30 | Yeda Res & Dev | Bistable type ii opsins and uses thereof |
IL266728B (en) | 2019-05-19 | 2020-11-30 | Yeda Res & Dev | Identification of recurrent mutant neopeptides |
WO2021005599A1 (en) | 2019-07-11 | 2021-01-14 | Kahr Medical Ltd. | Heterodimers and methods of use thereof |
IL268111A (en) | 2019-07-16 | 2021-01-31 | Fainzilber Michael | Methods of treating pain |
IL270800A (en) | 2019-11-20 | 2021-05-31 | Yeda Res & Dev | A method for treating Alzheimer's disease |
KR20220151168A (ko) | 2020-02-09 | 2022-11-14 | 엔엘씨 파르마 엘티디 | Sars-cov-2에 대한 신속한 검출 테스트 |
WO2021176457A1 (en) | 2020-03-05 | 2021-09-10 | Ariel Scientific Innovations Ltd. | Anti-hemorrhaging compositions |
WO2021186431A1 (en) | 2020-03-16 | 2021-09-23 | Yeda Research And Development Co. Ltd. | Peptide analogs and use of same in treating diseases, disorders or conditions associated with a mutant p53 protein |
IL276599A (en) | 2020-08-09 | 2022-03-01 | Yeda Res & Dev | T cell receptor unique to mage-a1 and its uses |
IL276627A (en) | 2020-08-10 | 2022-03-01 | Yeda Res & Dev | Compositions for diagnosis and treatment of coronavirus infections |
WO2022064494A2 (en) | 2020-09-23 | 2022-03-31 | Yeda Research And Development Co. Ltd. | Methods and compositions for treating coronaviral infections |
WO2022074656A1 (en) | 2020-10-07 | 2022-04-14 | Protalix Ltd. | Long-acting dnase |
MX2023005235A (es) | 2020-11-03 | 2023-10-16 | Protalix Ltd | Uricasa modificada y usos de la misma. |
JP2024506955A (ja) | 2021-02-18 | 2024-02-15 | イェダ リサーチ アンド デベロップメント カンパニー リミテッド | ワクチンを作製する方法 |
IL283563A (en) | 2021-05-30 | 2022-12-01 | Yeda Res & Dev | Profiling of amps for the diagnosis, monitoring and treatment of microbiome-related diseases |
WO2023031934A1 (en) | 2021-09-02 | 2023-03-09 | Yeda Research And Development Co. Ltd. | Agents that target the glycine arginine-rich domain of nucleolin and uses thereof |
WO2024038462A1 (en) | 2022-08-17 | 2024-02-22 | Yeda Research And Development Co. Ltd. | Novel bacteria-based delivery system for tace (adam17) selective biological inhibitor |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4086196A (en) * | 1975-03-28 | 1978-04-25 | Armour Pharmaceutical Company | Parathyroid hormone |
US4423037A (en) | 1982-05-13 | 1983-12-27 | The General Hospital Corporation | Inhibitors of peptide hormone action |
US4427827A (en) | 1982-10-20 | 1984-01-24 | Usv Pharmaceutical Corporation | Synthesis of hormone fragments |
FR2550204B1 (fr) * | 1983-08-05 | 1987-11-13 | Toyo Jozo Kk | Derives peptidiques de (nle8,nle1b, tyr34)-h-pth |
US4771124A (en) | 1987-05-26 | 1988-09-13 | Merck & Co., Inc. | Parathyroid hormone antagonists with simplified synthetic methodology |
CA2040264A1 (en) | 1990-04-12 | 1991-10-13 | Tatsuhiko Kanmera | Parathyroid hormone antagonists |
CA2087087C (en) | 1992-01-22 | 2000-07-18 | Burton H. Sage, Jr. | Molecules for iontophoretic delivery |
US5434246A (en) | 1992-03-19 | 1995-07-18 | Takeda Chemical Industries, Ltd. | Parathyroid hormone derivatives |
US5814603A (en) | 1992-06-12 | 1998-09-29 | Affymax Technologies N.V. | Compounds with PTH activity |
CA2098639A1 (en) | 1992-06-19 | 1993-12-20 | K. Anne Kronis | Bone stimulating, non-vasoactive parathyroid hormone variants |
US5589452A (en) | 1992-07-14 | 1996-12-31 | Syntex (U.S.A.) Inc. | Analogs of parathyroid hormone and parathyroid hormone related peptide: synthesis and use for the treatment of osteoporosis |
AU672790B2 (en) | 1992-07-15 | 1996-10-17 | Novartis Ag | Variants of parathyroid hormone and its fragments |
NZ257212A (en) | 1992-09-29 | 1996-11-26 | Inhale Therapeutic Syst | Parathyroid hormone formulations comprising a biologically active n-terminal fragment of the hormone |
US5556940A (en) | 1994-06-20 | 1996-09-17 | National Research Council Of Canada | Parathyroid hormone analogues for the treatment of osteoporosis |
CO4410206A1 (es) | 1994-07-28 | 1997-01-09 | Sandoz Ag | DERIVADOS DE PTH o PTHrP, SU PREPARACION Y COMPOSICIONES FARMACEUTICAS QUE LAS COMPRENDEN |
DE19508672A1 (de) * | 1995-03-10 | 1996-09-12 | Boehringer Mannheim Gmbh | Neue cyclische Parathormonfragmente, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel |
CA2178392A1 (en) | 1995-06-07 | 1996-12-08 | Robert W. Horst | Fail-fast, fail-functional, fault-tolerant multiprocessor system |
US5717062A (en) | 1995-06-07 | 1998-02-10 | Beth Israel Hospital Association | Cyclic analogs of PTH and PTHrP |
US5723577A (en) * | 1995-07-13 | 1998-03-03 | Biomeasure Inc. | Analogs of parathyroid hormone |
JP4122061B2 (ja) * | 1996-08-02 | 2008-07-23 | ナショナル リサーチ カウンシル オブ カナダ | 骨粗鬆症の治寮のための副甲状腺ホルモン類似体 |
-
1998
- 1998-05-13 CA CA002290443A patent/CA2290443A1/en not_active Abandoned
- 1998-05-13 EP EP98921200A patent/EP0986395A4/en not_active Withdrawn
- 1998-05-13 AP APAP/P/1999/001686A patent/AP9901686A0/en unknown
- 1998-05-13 AU AU73867/98A patent/AU746461B2/en not_active Ceased
- 1998-05-13 SK SK1515-99A patent/SK151599A3/sk unknown
- 1998-05-13 CN CN98806651A patent/CN1261281A/zh active Pending
- 1998-05-13 HU HU0003349A patent/HUP0003349A3/hu unknown
- 1998-05-13 WO PCT/US1998/009843 patent/WO1998051324A1/en not_active Application Discontinuation
- 1998-05-13 PL PL98336803A patent/PL336803A1/xx unknown
- 1998-05-13 JP JP54953698A patent/JP2001517957A/ja not_active Ceased
- 1998-05-13 BR BR9808786-0A patent/BR9808786A/pt not_active Application Discontinuation
- 1998-05-13 KR KR1019997010523A patent/KR100351213B1/ko not_active IP Right Cessation
- 1998-05-13 IL IL13290198A patent/IL132901A0/xx unknown
- 1998-05-13 EA EA199901025A patent/EA002819B1/ru not_active IP Right Cessation
- 1998-05-13 UA UA99126574A patent/UA62967C2/uk unknown
- 1998-05-14 ZA ZA984077A patent/ZA984077B/xx unknown
-
1999
- 1999-01-12 US US09/228,990 patent/US6472505B1/en not_active Expired - Fee Related
- 1999-11-12 NO NO995568A patent/NO995568L/no not_active Application Discontinuation
- 1999-11-12 OA OA9900247A patent/OA11216A/en unknown
- 1999-12-06 BG BG103957A patent/BG103957A/bg unknown
-
2002
- 2002-03-13 US US10/097,079 patent/US20020132973A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
KR20010012568A (ko) | 2001-02-15 |
PL336803A1 (en) | 2000-07-17 |
JP2001517957A (ja) | 2001-10-09 |
BG103957A (bg) | 2000-04-28 |
SK151599A3 (en) | 2000-09-12 |
US6472505B1 (en) | 2002-10-29 |
AU7386798A (en) | 1998-12-08 |
AU746461B2 (en) | 2002-05-02 |
WO1998051324A1 (en) | 1998-11-19 |
EP0986395A1 (en) | 2000-03-22 |
EP0986395A4 (en) | 2004-12-01 |
EA002819B1 (ru) | 2002-10-31 |
IL132901A0 (en) | 2001-03-19 |
KR100351213B1 (ko) | 2002-09-05 |
AP9901686A0 (en) | 1999-12-31 |
HUP0003349A3 (en) | 2001-12-28 |
CA2290443A1 (en) | 1998-11-19 |
BR9808786A (pt) | 2000-07-11 |
NO995568L (no) | 1999-12-29 |
OA11216A (en) | 2003-07-10 |
CN1261281A (zh) | 2000-07-26 |
NO995568D0 (no) | 1999-11-12 |
UA62967C2 (en) | 2004-01-15 |
US20020132973A1 (en) | 2002-09-19 |
HUP0003349A2 (hu) | 2001-01-29 |
EA199901025A1 (ru) | 2000-06-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL132901A0 (en) | Peptide parathyroid hormone analogs | |
IL130794A0 (en) | Analogs of parathyroid hormone | |
HUP9901718A3 (en) | Analogs of parathyroid hormone | |
GB9827348D0 (en) | Natriuretic peptide | |
HUP9901455A3 (en) | Somatostatin peptides | |
EP1039920A4 (en) | INSULIN ANALOGS ACYLATED BY FATTY ACID | |
ATE245165T1 (de) | Kristallines parathyroidhormon | |
LT99010A (en) | Parathyroid hormone analogues for the treatment of osteoporosis | |
EP0752873A4 (en) | MARKED PEPTIDE COMPOUNDS | |
EP0996458A4 (en) | SANDRAMYCIN ANALOG | |
IL121391A0 (en) | Synthesis of analogs of parathyroid hormone and parathyroid hormone related peptide | |
HUP0001477A3 (en) | Calcitonin receptor-binding peptides | |
GB9718110D0 (en) | Peptides | |
GB9825854D0 (en) | Peptide | |
IL139218A0 (en) | 2-aroyl-4-acyl-paclitaxel (taxol) analogs | |
GB9616700D0 (en) | Hormone supplement | |
EP0881907A4 (en) | FUNGICIDES IN THE FORM OF CYCLIC PEPTIDES | |
GB9700154D0 (en) | Peptides | |
EP0996626A4 (en) | Glycine-TRANSPORTER | |
EP0779813A4 (en) | PHOSPHONATES AND PARATHORMONE AGAINST OSTEOPOROSIS | |
EP0996457A4 (en) | PEPTIDES RELEASERS OF F.S.H. | |
HU0600009D0 (en) | Analogs of parathyroid hormone | |
ZA953315B (en) | New opioid peptide analogs | |
ZA978590B (en) | Antibodies against human parathyroid hormone related peptide. | |
GB9911577D0 (en) | A novel polypeptide hormone phosphatonin |